|
FAM49B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.55111512312578E-16 |
| Normal-vs-Stage2 |
1.84041670792112E-12 |
| Normal-vs-Stage3 |
3.88045151566985E-12 |
| Normal-vs-Stage4 |
2.76978440183484E-12 |
| Stage1-vs-Stage2 |
8.841800E-03 |
| Stage1-vs-Stage3 |
2.257800E-01 |
| Stage1-vs-Stage4 |
7.078300E-03 |
| Stage2-vs-Stage3 |
2.883800E-01 |
| Stage2-vs-Stage4 |
6.048800E-01 |
| Stage3-vs-Stage4 |
1.829780E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.33066907387547E-16 |
| Normal-vs-AfricanAmerican |
3.70219999989985E-07 |
| Normal-vs-Asian |
8.58690896166081E-12 |
| Caucasian-vs-AfricanAmerican |
6.763400E-01 |
| Caucasian-vs-Asian |
1.828580E-01 |
| AfricanAmerican-vs-Asian |
6.730200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.77080572427712E-13 |
| Normal-vs-Female |
8.42292902092368E-12 |
| Male-vs-Female |
4.607600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.65667479734566E-12 |
| Normal-vs-Age(41-60Yrs) |
2.53908005731773E-13 |
| Normal-vs-Age(61-80Yrs) |
8.10099987091917E-10 |
| Normal-vs-Age(81-100Yrs) |
2.563800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.988400E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.773800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.053800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.297600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.029900E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.395200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.888800E-01 |
| Classical-VS-Follicular |
1.121570E-01 |
| Classical-VS-Other |
2.678000E-01 |
| Classical-VS-Normal |
5.19240206386939E-11 |
| Tall-VS-Follicular |
6.709800E-01 |
| Tall-VS-Other |
5.524800E-01 |
| Tall-VS-Normal |
2.64029999996751E-06 |
| Follicular-VS-Other |
5.919600E-01 |
| Follicular-VS-Normal |
1.72639680329212E-12 |
| Other-VS-Normal |
2.589800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.28939089907954E-12 |
| Normal-vs-N1 |
2.89657187124703E-13 |
| N0-vs-N1 |
1.767190E-01 |
|
|
